Lucia Barbieri

Matricola:

$matricolaPersona.getData()

Presentazione:

  • Area di Competenza/Specialità

Cardiologia interventistica, Emodinamica

Interventistica coronarica percutanea con particolare attinenza a valutazione di imaging e funzionalità coronarica (iFR-FFR, IVUS).

Interventistica coronarica di lesioni complesse: chronic total occlusion (CTO), utilizzo di Rotablator.

 

  • Ruolo in struttura

Dirigente Medico

 

  • Libera professione

Attività di Libera Professione intra-moenia (per prenotazioni Tel. 0281844141)

 

 

Profili professionali:

$profiliProfessionionali.getData()

Skills:

$skills.getData()

Indirizzo:

Telefono:

Email:

$email.getData()

Siti internet:

Social:

Facebook - $accountFacebookPersona.getData()
Twitter - $accountTwitterPersona.getData()

Curriculum Vitae:

Scarica Cv

Lucia Barbieri

Cardiologo

Segreteria :

02-81844767

Lunedì - Mercoledì
16:00
17:00

Mail :

lucia.barbieri@asst-santipaolocarlo.it

Lunedì - Mercoledì
16:00
17:00
Note:

Ricevimento: Lunedì - Mercoledì dalle 16 alle 17 (previo contatto telefonico)

1.Verdoia M, Camaro C, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G. Mean platelet volume and the risk of periprocedural myocardial infarction in patients undergoing coronary angioplasty.Atherosclerosis. 2013 May;228(1):136-41. doi: 10.1016/j.atherosclerosis.2013.01.010. Epub 2013 Jan 29.

2.Rognoni A, Barbieri L, Cavallino C, Bacchini S, Veia A, Degiovanni A, Rametta F, Nardi F, Lazzero M, Lupi A, Bongo AS. Ranolazine: effects on ischemic heart.Recent Pat Cardiovasc Drug Discov. 2013 Dec;8(3):197-203. Review.

3.Verdoia M, Barbieri L, Schaffer A, Cassetti E, Di Giovine G, Bellomo G, Marino P, Sinigaglia F, De Luca G. “Platelet distribution width and the risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention”. J Thromb Thrombolysis. J Thromb Thrombolysis. 2014 Apr;37(3):345-52. 

4.Schaffer A, Verdoia M, Barbieri L, Aprami TM, Suryapranata H, Marino P, Luca GD; on behalf of the Novara Atherosclerosis Study Group (NAS).”High-density Lipoproteins and Coronary Artery disease: A Single-center Cohort Study”. Angiology. 2014 Sep;65(8):696-702.

5.Verdoia M, Secco GG, Barbieri L; Cassetti E, Schaffer A, Marino P, SuryapranataH, De Luca G on behalf of the Novara Atherosclerosis Study Group. “Platelet PlA1/PlA2 polymorphism and the risk of periprocedural myocardial infarction in patients undergoing elective PCI”. Platelets. 2014;25(5):367-72.

6.Verdoia M, Barbieri L, Schaffer A, Cassetti E, Marino P, Bellomo G, Sinigaglia F, De Luca G; Novara Atherosclerosis Study Group (NAS). Platelet-larger cell ratio and the risk of periprocedural myocardial infarction after percutaneous coronary revascularization.Heart Vessels. 2015 Jan;30(1):20-7.

7.Verdoia M, Schaffer A, Barbieri L, Cassetti E, Piccolo R, Galasso G, Marino P, Sinigaglia F, De Luca G. Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials.J Cardiovasc Pharmacol. 2014 Apr;63(4):339-50.

8.Verdoia M, Schaffer A, Cassetti E, Barbieri L, Di Giovine G, Marino P, De Luca G; Novara Atherosclerosis Study Group (NAS). MTHFR polymorphism and risk of periprocedural myocardial infarction after coronary stenting.Nutr Metab Cardiovasc Dis. 2014 May;24(5):532-7.

9.Verdoia M, Secco GG, Cassetti E, Schaffer A, Barbieri L, Perrone-Filardi P, Marino P, Suryapranata H, Sinigaglia F, De Luca G. Platelet PIA1/PIA2 polymorphism and the risk of periprocedural myocardial infarction in patients with acute coronary syndromes undergoing coronary angioplasty.Blood Coagul Fibrinolysis. 2014 Mar;25(2):107-13.

10.Verdoia M, Schaffer A, Barbieri L, Cassetti E, Nardin M, Bellomo G, Marino P, Sinigaglia F, De Luca G; Novara Atherosclerosis Study (NAS) group. Diabetes, glucose control and mean platelet volume: a single-centre cohort study.Diabetes Res Clin Pract. 2014 May;104(2):288-94.

11.Verdoia M, Cassetti E, Schaffer A, Barbieri L, Giovine GD, Nardin M, Marino P, Sinigaglia F, Luca GD; NovaraAtherosclerosis Study Group (NAS). Relationship between glycoprotein IIIa platelet receptor gene polymorphism and coronary artery disease.Angiology. 2015 Jan;66(1):79-85.

12.Verdoia M, Barbieri L, Schaffer A, Cassetti E, Nardin M, Bellomo G, Aimaretti G, Marino P, Sinigaglia F, De Luca G; NovaraAtherosclerosis Study Group (NAS). Impact of diabetes on uric acid and its relationship with the extent of coronary artery disease and platelet aggregation: a single-centre cohort study.Metabolism. 2014 May;63(5):640-6.

13.Verdoia M, Schaffer A, Barbieri L, Cassetti E, Di Giovine G, Marino P, De Luca G; Novara Atherosclerosis Study Group (NAS). Homocysteine and risk of periprocedural myocardial infarction in patients undergoing coronary stenting.J Cardiovasc Med (Hagerstown). 2015 Feb;16(2):100-5

14.Barbieri L, Verdoia M, Schaffer A, Nardin M, Marino P, De Luca G. The role of statins in the prevention of contrast induced nephropathy: a meta-analysis of 8 randomized trials.J Thromb Thrombolysis. 2014 Nov;38(4):493-502.

15.Verdoia M, Schaffer A, Cassetti E, Barbieri L, Di Ruocco MV, Perrone-Filardi P, Marino P, De Luca G; Novara Atherosclerosis Study Group (NAS). Glycosylated hemoglobin and coronary artery disease in patients without diabetes mellitus.Am J Prev Med. 2014 Jul;47(1):9-16.

16.Verdoia M, Schaffer A, Sartori C, Barbieri L, Cassetti E, Marino P, Galasso G, De Luca G. Vitamin D deficiency is independently associated with the extent of coronary artery disease.Eur J Clin Invest. 2014 Jul;44(7):634-42.

17.Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Marino P, De Luca G; Novara Atherosclerosis Study Group (NAS). Uric acid and risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention.Diabetes Metab Res Rev. 2014 May;30(4):297-304.

18.Barbieri L, Verdoia M, Schaffer A, Niccoli G, Perrone-Filardi P, Bellomo G, Marino P, Suryapranata H, De Luca G. Elevated homocysteine and the risk of contrast-induced nephropathy: a cohort study.Angiology. 2015 Apr;66(4):333-8.

19.Verdoia M, Barbieri L, Schaffer A, Cassetti E, Di Giovine G, Nardin M, Bellomo G, Marino P, De Luca G; NovaraAtherosclerosis Study Group (NAS). Effect of diabetes mellitus on periprocedural myocardial infarction in patients undergoing coronary stent implantation.Diabetes Metab Res Rev. 2015 Jan;31(1):85-92.

20.Verdoia M, Schaffer A, Barbieri L, Sinigaglia F, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Eosinophils count and periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions.Atherosclerosis. 2014 Sep;236(1):169-74.

21.Barbieri L, Verdoia M, Schaffer A, Cassetti E, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI.Nutr Metab Cardiovasc Dis. 2015 Feb;25(2):181-6.

22.Barbieri L, Verdoia M, Schaffer A, Cassetti E, Di Giovine G, Marino P, Suryapranata H, De Luca G. Pre-diabetes and the risk of contrast induced nephropathy in patients undergoing coronary angiography or percutaneous intervention.Diabetes Res Clin Pract. 2014 Dec;106(3):458-64.

23.Verdoia M, Schaffer A, Barbieri L, Bellomo G, Marino P, Sinigaglia F, Suryapranata H, De Luca G; Novara Atherosclerosis Study (NAS) group. Impact of age on mean platelet volume and its relationship with coronary artery disease: a single-centre cohort study.Exp Gerontol. 2015 Feb;62:32-6.

24.Verdoia M, Schaffer A, Barbieri L, Aimaretti G, Marino P, Sinigaglia F, Suryapranata H, De Luca G; on behalf of the Novara Atherosclerosis Study Group (NAS). Impact of diabetes on neutrophil-to-lymphocyte ratio and its relationship to coronary artery disease.Diabetes Metab. 2015 Sep;41(4):304-11.

25.Schaffer A, Verdoia M, Cassetti E, Barbieri L, Perrone-Filardi P, Marino P, De Luca G. Impact of red blood cells count on the relationship between high density lipoproteins and the prevalence and extent of coronary artery disease: a single centre study.J Thromb Thrombolysis. 2015 Jul;40(1):69.

26.Verdoia M, Schaffer A, Pergolini P, Rolla R, Barbieri L, Bellomo G, Sinigaglia F, Marino P, Suryapranata H, De Luca G; on behalf of the Novara Atherosclerosis Study Group (NAS). Homocysteine levels influence platelet reactivity in coronary artery disease patients treated with acetylsalicylic acid.J Cardiovasc Pharmacol. 2015 Jul;66(1):35-40.

27.Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Marino P, Suryapranata H, De Luca G; of the Novara Atherosclerosis Study Group (NAS). Glycosylated hemoglobin and the risk of periprocedural myocardial infarction in non-diabetic patients.J Diabetes Complications. 2015 May-Jun;29(4):517-22.

28.Verdoia M, Schaffer A, Barbieri L, Suryapranata H, De Luca G. Bivalirudin as compared to unfractionated heparin in patients undergoing percutaneous coronary revascularization: A meta-analysis of 22 randomized trials.Thromb Res. 2015 May;135(5):902-15.

29.Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Impact of gender difference on vitamin D status and its relationship with the extent of coronary artery disease.Nutr Metab Cardiovasc Dis. 2015 May;25(5):464-70.

30.Verdoia M, Barbieri L, Giovine GD, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Neutrophil to Lymphocyte Ratio and the Extent of Coronary Artery Disease: Results From a Large Cohort Study.Angiology. 2016 Jan;67(1):75-82. 

31.Barbieri L, Verdoia M, Schaffer A, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Impact of sex on uric acid levels and its relationship with the extent of coronary artery disease: A single-centre study.Atherosclerosis. 2015 Jul;241(1):241-8. 

32.Verdoia M, Sartori C, Pergolini P, Nardin M, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G;Novara Atherosclerosis Study Group (NAS). Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation.Vascul Pharmacol. 2016 Feb;77:48-53.

33.Barbieri L, Verdoia M, Schaffer A, Marino P, De Luca G.[Two catheters for one coronary perforation].G Ital Cardiol (Rome). 2015 Feb;16(2):112-5.

34.Verdoia M, Barbieri L, Suryapranata H, De Luca G. Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview.Platelets. 2016;27(2):93-104.

35.Nardin M, Verdoia M, Sartori C, Pergolini P, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G. Body Mass Index and platelet reactivity during dual antiplatelet therapy with clopidogrel or ticagrelor.J Cardiovasc Pharmacol. 2015 Oct;66(4):364-70. 

36.Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Schaffer A, Bellomo G, Marino P, Suryapranata H, De Luca G.Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.Expert Opin Pharmacother. 2015 Aug;16(12):1739-47. 

37.Verdoia M, Schaffer A, Barbieri L, Montalescot G, Collet JP, Colombo A, Suryapranata H, Luca G. Optimal Duration of Dual Antiplatelet Therapy After DES Implantation: A Meta-Analysis of 11 Randomized Trials.Angiology. 2016 Mar;67(3):224-38.

38.Di Giovine G, Verdoia M, Barbieri L, Schaffer A, Aimaretti G, Bellomo G, Marino P, Suryapranata H, Sinigaglia F, De Luca G; Novara Atherosclerosis Study (NAS) group. Impact of diabetes on fibrinogen levels and its relationship with platelet reactivity and coronary artery disease: A single-centre study.Diabetes Res Clin Pract. 2015 May 18. 

39.Verdoia M, Sartori C, Pergolini P, Nardin M, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G. Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes.J Thromb Thrombolysis. 2016 May;41(4):663-70.

40.Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Schaffer A, Bellomo G, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy.Cardiovasc Drugs Ther. 2015 Oct;29(5):443-450.

41.Verdoia M, Barbieri L, Schaffer A, Nardin M, Suryapranata H, De Luca G. Acetylsalicylic acid desensitization in patients with coronary artery disease: A comprehensive overview of currently available protocols.Vascul Pharmacol. 2016 May;80:43-9.

42.Verdoia M, Pergolini P, Rolla R, Nardin M, Schaffer A, Barbieri L, Marino P, Bellomo G, Suryapranata H, De Luca G. Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.J Thromb Haemost. 2016 Jan;14(1):57-64.

43.Barbieri L, Pergolini P, Verdoia M, Rolla R, Nardin M, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.Vascul Pharmacol. 2016 Apr;79:11-5. 

44.Verdoia M, Nardin M, Sartori C, Pergolini P, Rolla R, Barbieri L, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Impact of atorvastitin or rosuvastatin co-administration on platelet reactivity in patients treated with dual antiplatelet therapy. Atherosclerosis. 2015 Dec;243(2):389-94.

45.Barbieri L, Verdoia M, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group. Contrast volume to creatinine clearance ratio for the prediction of contrast-induced nephropathy in patients undergoing coronary angiography or percutaneous intervention.Eur J Prev Cardiol. 2016 Jun;23(9):931-7.

46.Barbieri L, Verdoia M, Pergolini P, Nardin M, Rolla R, Marino P, Bellomo G, Suryapranata H, De Luca G. Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor. Nutr Metab Cardiovasc Dis. 2016 Apr;26(4):352-8.

47.Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Daffara V, Marino P, Bellomo G, Suryapranata H, Luca GD; Novara Atherosclerosis Study Group (NAS). Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy.Cardiovasc Drugs Ther. 2016 Apr;30(2):143-50.

48.Schaffer A, Verdoia M, Barbieri L, Cassetti E, Suryapranata H, De Luca G. Impact of Diabetes on Homocysteine Levels and Its Relationship with Coronary Artery Disease: A Single-Centre Cohort Study.Ann Nutr Metab. 2016;68(3):180-8.

49.Verdoia M, Pergolini P, Nardin M, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G. Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy. J Thromb Thrombolysis. 2016 Aug;42(2):245-53. 

50.Verdoia M, Barbieri L, Schaffer A, Bellomo G, Marino P, De Luca G; Novara Atherosclerosis Study (NAS) group. Impact of renal function on mean platelet volume and its relationship with coronary artery disease: A single-centre cohort study.Thromb Res. 2016 May;141:139-44.

51.Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Schaffer A, Bellomo G, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor. Cardiovasc Ther. 2016 Aug;34(4):209-15

52.Nardin M, Verdoia M, Pergolini P, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.Nutr Metab Cardiovasc Dis. 2016 Jul;26(7):567-74.

53.Nardin M, Verdoia M, Sartori C, Pergolini P, Rolla R, Barbieri L, Schaffer A, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients.Thromb Res. 2016 Jul;143:45-9

54.Verdoia M, Schaffer A, Barbieri L, Suryapranata H, De Luca G. Bivalirudin Versus Unfractionated Heparin in Acute Coronary Syndromes: An Updated Meta-analysis of Randomized Trials.Rev Esp Cardiol (Engl Ed). 2016 Aug;69(8):732-45.

55.Nardin M, Verdoia M, Schaffer A, Barbieri L, Marino P, De Luca G; Novara Atherosclerosis Study Group (NAS). Vitamin D status, diabetes mellitus and coronary artery disease in patients undergoing coronary angiography.Atherosclerosis. 2016 Jul;250:114-21

56.Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Bellomo G, Marino P, Suryapranata H, De Luca G. Impact of neutrophil-to-lymphocyte ratio on periprocedural myocardial infarction in patients undergoing non-urgent percutaneous coronary revascularisation.Neth Heart J. 2016 Jul;24(7-8):462-74.

57.Camaro C, Damen SA, Brouwer MA, Kedhi E, Lee SW, Verdoia M, Barbieri L, Rognoni A, van T Hof AW, Ligtenberg E, de Boer MJ, Suryapranata H, De Luca G. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.Am Heart J. 2016 Aug;178:37-44.

58.Verdoia M, Pergolini P, Rolla R, Sartori C, Nardin M, Schaffer A, Barbieri L, Daffara V, Marino P, Bellomo G, Suryapranata H, Luca GD; Novara Atherosclerosis Study Group (NAS). Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.Platelets. 2016 Sep;27(6):576-82.

59.Barbieri L, Verdoia M, Nardin M, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Gender Difference in the Risk of Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography or Percutaneous Coronary Intervention.Angiology. 2017 Jul;68(6):542-546.

60.Barbieri L, Verdoia M, Schaffer A, Suryapranata H, De Luca G. Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies.Cardiovasc Drugs Ther. 2016 Dec;30(6):611-622.

61.Verdoia M, Pergolini P, Rolla R, Nardin M, Schaffer A, Barbieri L, Daffara V, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease.Thromb Res. 2017 Feb;150:90-95.

62.Verdoia M, Barbieri L, Parodi G, Bellandi B, Schaffer A, Suryapranata H, De Luca G. Impact of anticoagulation strategy with bivalirudin or heparin on nonaccess site bleeding in percutaneous coronary interventions: A meta-analysis of randomized trials.Catheter Cardiovasc Interv. 2017 Oct 1;90(4):553-565.

63.Nardin M, Verdoia M, Barbieri L, Schaffer A, Suryapranata H, De Luca G. Radial vs femoral approach in acute coronary sindrome: a meta-analysis of randomized trials. Curr Vasc Pharmacol 2017;16(1):79-92.

64.Verdoia M, Barbieri L, Nardin M, Suryapranata H, De Luca G. Dual versus single antiplatelet regimen with or without anticoagulation in transcatheter aortic valve replacement: indirect comparison and meta-analysis. Rev Esp Cardiol (Engl Ed). 2018 Apr;71(4):257-266.

65.Rognoni A, Cavallino C, Mennuni MG, Barbieri L, Rosso R, Rametta F, Nardi F, Lupi A, Bongo AS. Out-of-hospital cardiac arrest: always coronary angiography? Expert Rev Cardiovasc Ther. 2017 Nov;15(11):847-851.

66.De Luca G, Verdoia M, Barbieri L, Marino P, Suryapranata H. Resting Pd/Pa and haemodynamic relevance of coronary stenosis as evacuate by fractional flow reserve. Coron Artery Dis. 2018 Mar;29(2):138-144.

67.Verdoia M, Pergolini P, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G. Impact of long term dual antiplatelet therapy on immmature platelet count and platelet reactivity. Angiology 2017 Jan 1:3319717736407. doi:10.1177/0003319717736407. [Epub ahead of print]

68.Nardin M, Verdoia M, Pergolini P, Rolla R, Barbieri L, Marino P, Bellomo G, Kedhi E, Suryapranata H, Carriero A, De Luca G. Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients. Pharmacol Res. 2018 Mar;129:27-33.

69.Verdoia M, Pergolini P, Barbieri L, Rolla R, Nardin M, Negro F, Suryapranata H, De Luca G. Impact of pre-procedural dual antiplatelet therapy on periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions with adjunctive tirofiban. Thromb Res. 2018 Apr;164:17-23.

70.Verdoia M, Barbieri L, Kedhi E, Suryapranata H, De Luca G. Percutaneous versus surgical revascularization for left main or multi vessel coronary artery disease: results from a large-scale Meta analysis in the era of drug-eluting stents.

71.Nardin M, Verdoia M, Barbieri L, De Luca G; Novara Atherosclerosis Study Group (NAS). Impact of metabolic syndrome on mean platelet volume and its relationship with coronary artery disease.Platelets. 2018 Jul 26:1-9. doi: 10.1080/09537104.2018.1499885. [Epub ahead of print]

72.Barbieri L, Verdoia M, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Impact of vascular access on the development of contrast induced nephropathy in patients undergoing coronary angiography and/or percutaneous coronary intervention.Int J Cardiol. 2018 Aug 10. pii: S0167-5273(17)35319-6. doi: 10.1016/j.ijcard.2018.08.026. [Epub ahead of print]

73.Verdoia M, Erbetta R, Sagazio E, Barbieri L, Negro F, Suryapranata H, Kedhi E, De Luca G; NovaraAtherosclerosis Study Group (NAS). Impact of increasing dose of intracoronary adenosine on peak hyperemia duration during fractional flow reserve assessment.Int J Cardiol. 2018 Oct 2. pii: S0167-5273(18)30810-6. doi: 10.1016/j.ijcard.2018.09.088. [Epub ahead of print]